Answers are grounded in this paper and cite their sources.
Pharmacologic evidence shows cytisinicline reduces nausea in smoking cessation, suggesting improved tolerability for sensitive individuals.
This study provides pharmacologic evidence that cytisinicline selectively interacts with the α4β2 nicotinic receptor while exhibiting minimal interaction with the 5-HT3 receptor, a key mechanism potentially underlying its improved gastrointestinal tolerability. These findings help explain the lower nausea rates observed in clinical trials and support cytisinicline as a promising alternative to varenicline for smoking cessation, particularly in individuals sensitive to medication-related side effects. This receptor-specific profile may enhance treatment adherence and expand the appeal of pharmacologic smoking cessation strategies.
No takes yet. Share an insight, caveat, or question.
Rubinstein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: